FDA approves new influenza vaccine production facility
This article was originally published in The Gold Sheet
On May 6 FDA announced approval of a new influenza vaccine manufacturing facility in Swiftwater, Pa., for the production of the influenza H1N1 (swine flu) virus. The facility is owned and operated by Sanofi Pasteur, which is one of the nation's largest seasonal flu vaccine producers as well as one of the world's earliest developers of vaccines. Sanofi will use the new facility to manufacture Fluzone, an egg-based influenza vaccine. The company finished constructing the $150 million, 140,000 square foot plant in July 2007 and the facility is now operating. On another front, the vaccine giant just announced that it just started construction of a new vaccine production center in Neuville-sur-Saone, in southeastern France, for the tropical dengue virus
You may also be interested in...
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.
The withdrawal of the marketing authorization application for Dexamethasone Taw as a treatment for COVID-19 patients was revealed today in the January meeting agenda of the European Medicines Agency’s human medicines committee, the CHMP.